R-MDMA HCl Form I Crystallization for Stable Polymorph Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to identify stable polymorphic crystalline forms of R-MDMA HCl and produce compositions comprising stable crystalline forms of R-MDMA HCl, as existing reports primarily focus on the hydrochloride salt of racemic MDMA.
Innovation Solution
A process is developed for the preparation of enantiopure (R)-3,4-methylenedioxymethamphetamine (MDMA) HCl salt, characterized by specific X-ray Powder Diffraction patterns, monoclinic crystal system, and high solubility in water, with a stable crystalline form (Form I) that exhibits physical stability under high humidity and defined thermal properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing synthesis methods for racemic MDMA hydrochloride are used, then production of MDMA salt is achieved, but stable polymorphic crystalline forms of enantiopure R-MDMA HCl are not obtained
Solution Approach 1:
The patent applies parameter changes by modifying crystallization conditions including solvent selection (ether, ethanol, isopropanol, acetonitrile, or their mixtures), temperature profiles (cooling from room temperature to 0°C or -20°C), and pH control during the conversion step to reliably produce Form I crystals of R-MDMA HCl with specific diffraction patterns and physical properties
Solution Approach 2:
The patent employs preliminary action by first establishing enantiopure R-MDMA through asymmetric synthesis using chiral catalysts or resolving agents before proceeding to salt formation and crystallization, ensuring the starting material has the required optical purity (≥98% ee) before final crystal formation
2Manufacturing precision
If enantiopure R-MDMA is synthesized, then optical purity is improved, but characterization and identification of stable crystalline forms becomes more difficult
Solution Approach 1:
The patent uses X-ray powder diffraction (XRPD) patterns as a fingerprinting method to characterize and identify Form I crystals, with specific diffraction peaks at 2θ angles of 7.9±0.2°, 14.0±0.2°, 15.8±0.2°, 17.5±0.2°, 20.5±0.2°, 24.8±0.2°, 26.7±0.2°, 29.0±0.2°, and 37.9±0.2° serving as definitive identification markers for the stable polymorphic form
Solution Approach 2:
The patent replaces complex manual characterization methods with automated analytical techniques including XRPD for crystal structure identification, DSC for thermal behavior analysis (melting point 186±2°C), and HPLC for optical purity quantification, enabling precise and reproducible characterization of enantiopure crystalline forms
3Reliability
If stable crystalline form R-MDMA HCl Form I is produced, then solubility and physical stability are improved, but the process requires specific controlled conditions
Solution Approach 1:
The patent optimizes process parameters including maintaining pH 2-5 during salt formation, controlling crystallization temperature (0°C to -20°C), selecting specific solvents (ether, ethanol, isopropanol, acetonitrile, or mixtures), and controlling relative humidity (20-80% RH) and temperature (20-40°C) during drying to ensure formation of stable Form I crystals with high solubility (>110 mg/mL in water) and physical stability
Solution Approach 2:
The patent employs self-service by allowing the crystallization process to naturally form the stable Form I polymorph through controlled supersaturation and slow cooling, where the system self-organizes into the thermodynamically most stable crystal structure under the specified conditions, minimizing need for intensive process intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process provides R-MDMA HCl Form I with high optical purity and stability, offering improved solubility and physical properties suitable for pharmaceutical applications.
Implementation Method 1
R-MDMA HCl Form I is characterized by an X-ray Powder Diffraction (XPRD) pattern substantially similar to 204 in FIG. 2A and FIG. 2B
Implementation Method 2
R-MDMA HCl Form I is characterized by peaks in an XPRD pattern at 17.5±0.2, 24.8±0.2, 15.8±0.2, 20.5±0.2, 14.0±0.2, 26.7±0.2, 29.0±0.2, 37.9±0.2, 7.9±0.2° 2θ
Implementation Method 3
R-MDMA HCl Form I exhibits a Differential Scanning calorimetry (DSC) thermogram comprising an endotherm peak at 186° C. with an onset at 185° C.
Implementation Method 4
R-MDMA HCl Form I exhibits 0.2±0.1% weight loss between 52-231° C. as measured by thermogravimetric (TGA) analysis
Implementation Method 5
R-MDMA HCl Form I exhibits 5.28±0.02% weight gain from 5-95% relative humidity (RH) and a 5.35±0.02% weight loss from 95-5% RH
Data Source
AI summary
Provided herein is a process for the preparation of (R)-3,4 methylenedioxymethamphetamine HCl Form 1.